Nucleic Acids Res+Nat Commun:艾滋病毒可以成功治愈癌症?是“天方夜谭”还是“有据可循”

2017-10-31 佚名 肿瘤免疫细胞治疗资讯

来自加拿大的研究员Linda Chelico等表示:“我们的发现可能会改变治疗癌症的方式。”《Nucleic Acids Res》和《Nat Commun》刊登了她的最新研究成果。

来自加拿大的研究员Linda Chelico等表示:“我们的发现可能会改变治疗癌症的方式。”《Nucleic Acids Res》和《Nat Commun》刊登了她的最新研究成果。

在此次研究中,研究人员发现了APOBEC3家族中的三种酶,再加上免疫系统中的其他酶,总共七种造成突变的酶,它们就是促使癌症发生的罪魁祸首。根据此次研究结果,研究人员们将会开发抑制剂,来抑制酶的作用。

在之前的研究中,科学家们已经了解到与癌症基因突变有关的酶可以保护身体不受病毒侵害,但直到现在,这些酶是如何使基因突变的仍不得而知。

“我们所研究的酶可以建立良好的身体防御系统,但是也有一些过分活跃,在错误的时间出现在错误的地方。与艾滋病毒DNA相关的酶试图阻止艾滋病病毒在身体中复制,但是艾滋病毒也有自己的防御系统,由于无法对抗艾滋病毒,这些酶就会在身体中继续扫描,然而很不幸的是,它们错误的打开了某些细胞类型,使健康的细胞发生了突变。即使身体的免疫系统试图阻止这一情况的发生,但是也无济于事。

本来想要消灭艾滋病毒的酶却引起了癌症?这是天方夜谭吗?研究人员发现这些酶的日常行为是只攻击单链DNA病毒,在此次试验中,研究人员成功将这些酶分离出来,他们希望可以了解这些酶背后的机制,是否可以通过艾滋病毒改变这些酶的功能,从而改变引发癌症的基因突变,目前,研究人员已经成功开发出了对抗这些酶的“新武器”,让我们一起来期待结果吧!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1882586, encodeId=a6c5188258633, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 01 09:47:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911423, encodeId=b2a6191142326, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Tue Mar 13 04:47:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087180, encodeId=8b41208e18099, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 13 08:47:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991582, encodeId=1b4c1991582a4, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Jul 06 13:47:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257578, encodeId=daf625e5786d, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 31 21:45:54 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2018-06-01 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1882586, encodeId=a6c5188258633, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 01 09:47:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911423, encodeId=b2a6191142326, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Tue Mar 13 04:47:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087180, encodeId=8b41208e18099, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 13 08:47:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991582, encodeId=1b4c1991582a4, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Jul 06 13:47:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257578, encodeId=daf625e5786d, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 31 21:45:54 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2018-03-13 wodejia-dayu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1882586, encodeId=a6c5188258633, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 01 09:47:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911423, encodeId=b2a6191142326, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Tue Mar 13 04:47:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087180, encodeId=8b41208e18099, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 13 08:47:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991582, encodeId=1b4c1991582a4, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Jul 06 13:47:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257578, encodeId=daf625e5786d, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 31 21:45:54 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-12-13 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1882586, encodeId=a6c5188258633, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 01 09:47:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911423, encodeId=b2a6191142326, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Tue Mar 13 04:47:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087180, encodeId=8b41208e18099, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 13 08:47:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991582, encodeId=1b4c1991582a4, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Jul 06 13:47:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257578, encodeId=daf625e5786d, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 31 21:45:54 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2018-07-06 xlxchina
  5. [GetPortalCommentsPageByObjectIdResponse(id=1882586, encodeId=a6c5188258633, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jun 01 09:47:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911423, encodeId=b2a6191142326, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Tue Mar 13 04:47:00 CST 2018, time=2018-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087180, encodeId=8b41208e18099, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 13 08:47:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991582, encodeId=1b4c1991582a4, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Fri Jul 06 13:47:00 CST 2018, time=2018-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=257578, encodeId=daf625e5786d, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Oct 31 21:45:54 CST 2017, time=2017-10-31, status=1, ipAttribution=)]
    2017-10-31 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

相关资讯

J Neurovirol:数学模型揭示了大脑中艾滋病毒感染的奥秘

由UAlberta研究团队开发的一种新的数学模型揭示了大脑中艾滋病毒感染的进展,临床医生和研究人员正在开发鼻喷雾剂来更有效地进行药物治疗。

J INFECT DIS实现国家艾滋病毒/艾滋病战略将挽救患者生命

由马萨诸塞州总医院(MGH)调查人员组成的分析显示,到2020年实现国家艾滋病战略(NHAS)的治疗目标,不仅可以防止数十万新的感染和死亡,而且还将显示出卓越的价值。他们在“传染病杂志”上发表的研究发现,符合NHAS目标--90%的艾滋病毒感染者知道他们的诊断,其中80%通过抗逆转录病毒药物治疗(ART)实现病毒学抑制。

艾滋病毒和腹泻:原因和关系

【腹泻和艾滋病毒之间的关系是什么?】腹泻是用于描述肠运动的重量,体积和频率的增加的术语,其通常是松散的和水样的。

AM J PREV MED:到2025年结束HIV流行的大计划!

一项新的研究描述了十年前可能似乎无法实现的雄心勃勃但可行的途径:结束美国艾滋病流行。使用预防监测数据来模拟艾滋病毒发病率,流行率和死亡率,布里格姆和妇女医院的研究人员制定了目标,特别是到2020年将新感染减少到21,000个人,到2025年将减少到12,000个人,这将标志着结束艾滋病毒/艾滋病流行的过渡。他们的研究结果发表在“美国预防医学杂志”上。

JAMA Pediatr:十年期间美国婴儿发生围产期艾滋病毒感染现状

目前,可以通过抗逆转录病毒治疗和预防来减少人类免疫缺陷病毒(HIV)在围产期的传播。尚需对围产期艾滋病毒传播和漏失预防机会的数据进行统计,以监测消除母婴传播艾滋病毒的进展情况。近期,一项发表在杂志JAMA Pediatr上的研究旨在评估美国出生的婴儿中发生围产期艾滋病毒病例的数量。此项研究的数据来自国家艾滋病监测系统,统计2002年至2013年(截至2015年12月31日期间),美国(包括哥伦比亚

J Hepatol:每天喝三杯以上的咖啡,是艾滋病毒和丙肝病毒患者的救星

感染人类免疫缺陷病毒(HIV)和丙型肝炎病毒(HCV)的患者,处于终末期肝病的特定风险和心血管疾病和癌症的更大风险。此外,艾滋病毒感染加速了慢性丙型肝炎进展为纤维化,发展为肝硬化和终末期肝病。在这些HIV-HCV感染患者中,根据“肝病学杂志”发表的一项新研究,每天至少喝三杯咖啡,死亡的风险降低一半。